Talecris prices IPO

Talecris Biotherapeutics Inc. (NASDAQ:TLCR) raised $550 million through the sale of 28.9 million shares at $19 in an IPO underwritten by Morgan Stanley; Goldman Sachs; Citigroup; JPMorgan; Wells Fargo; Barclays Capital; and UBS. The price came in at the midpoint of the proposed $18-$20 range and values the company at $2.3 billion. Selling shareholder Talecris Holdings, which is owned by Cerberus-Plasma Holdings, offered 21.1 million shares, up from a previously proposed 15.8 million. Talecris filed in 2007 to raise up to $1 billion. Talecris was up $2.15 (11%) to $21.15 on 20.3 million shares in its first day of trading on Thursday. ...